Morgan Stanley (MS) grew with the stock adding 1.46% or $0.63 to close at $43.85 on active trading volume of 9.14M compared its three months average trading volume of 12.05M. The New York New York 10036 based company operating under the Investment Brokerage – National industry has been trending up for the last 52 weeks, with the shares price now 55.02% up for the period and up by 3.79% so far this year. With price target of $42.02 and a 111.06% rebound from 52-week low, Morgan Stanley has plenty of upside potential, making it a hold with a view buy.
Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. The companys Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides sales and trading services, such as sales, financing, and market-making services in equity securities and fixed income products, including foreign exchange and commodities, as well as prime brokerage services; and corporate lending services, credit products, and investments and research services. Its Wealth Management segment offers various financial services and solutions covering brokerage and investment advisory services, market-making services in fixed income securities, financial and wealth planning services, annuity and insurance products, credit and other lending products, and banking and retirement plan services to individual investors, small-to-medium sized businesses, and institutions. The companys Investment Management segment provides various investment strategies and products comprising asset management, including equity, fixed income, liquidity, alternatives, and managed futures products. This segment is also involved in merchant banking and real estate investing businesses. Morgan Stanley was founded in 1924 and is headquartered in New York, New York.
Gilead Sciences Inc. (GILD) dropped $-0.52 to close the day at a new closing price of $75.49, a -0.68% decrease in value from its previous closing price that moved the stock 7.27% above its 52 week low of $70.83. A total of 8.97M shares exchanged hands during the day compared with its three month average trading volume of 9.61M. The stock, which fluctuated between $75.41 and $76.5 during the day, currently situated -25.44% below its 52 week high. The stock is up by 4.84% in the past one month and down by -0.31% over the past three months. With a one year target estimate of $95.19 and RSI of 57.61, the stock still has upside potential, making it a hold for now.
Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The companys products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Medtronic plc (MDT) shares were up in last trading by 2.88% to $72.87. It experienced higher than average volume on day. The stock increased in value by almost 1.86% over the past week and grew 1.66% in the past month. It is currently trading -3.94% below its 50 day moving average and -10.27% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -17.88% decrease in value from its one year high of $89.27. The RSI indicator value of 47.16, lead us to believe that it is a hold for now.
Medtronic plc manufactures and sells device-based medical therapies worldwide. The companys Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators and cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, peripheral vascular intervention products, and products to treat superficial and deep venous diseases. Its Minimally Invasive Therapies Group segment provides gastrointestinal diagnostics, ablation, and interventional lung solutions; stapling, vessel sealing, and other surgical instruments; sutures; electrosurgery products; hernia mechanical devices; mesh implants; products for patient monitoring and recovery; sensors; monitors; compression and dialysis, enteral feeding, and wound care products; and operating room supplies, electrodes, needles, syringes, and sharps disposals. The companys Restorative Therapies Group segment offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, throat, and neurological disorders; systems that incorporate advanced energy surgical instruments; products for haemostatic sealing of soft tissue and bone; and image-guided surgery and intra-operative imaging systems. Its Diabetes Group segment provides insulin pumps and consumables; continuous glucose monitoring systems; and Web-based therapy management software solutions. It serves hospitals, physicians, clinicians, and patients. Medtronic plc was founded in 1949 and is headquartered in Dublin, Ireland.